Get startedLog in
    Picture of Sangui Biotech International logo

    SGBI — Sangui Biotech International Income Statement

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Sangui Biotech International, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

    2018
    June 30th
    2019
    June 30th
    2020
    June 30th
    2021
    June 30th
    2022
    June 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:10-K10-K10-K10-K10-K
    Standards:
    USG
    USG
    USG
    USG
    USG
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue0.0770.0880.0290.0660.069
    Cost of Revenue
    Gross Profit0.0770.0880.029——
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Total Operating Expenses0.2850.4260.2170.2170.213
    Operating Profit-0.208-0.338-0.188-0.151-0.144
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes-0.216-0.343-0.199-0.204-0.063
    Provision for Income Taxes
    Net Income After Taxes-0.216-0.343-0.199-0.204-0.063
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income-0.202-0.324-0.193-0.199-0.059
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-0.202-0.324-0.193-0.199-0.059
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.001-0.002-0.001-0.001-0